Aptimmune Biologics Develops the Future of Disease Protection for America’s Swine Industry

Aptimmune Biologics

Headquartered in St. Louis, MO, Aptimmune Biologics specializes in developing autogenous mucosal vaccines for viral diseases. The company is focused on creating valuable, safe, and effective vaccines that are costly to America’s swine industy. Aptimmune believes that mucosal vaccines are the future of vaccine-derived immunity, providing a faster, higher level and longer lasting immune response and disease protection to ensure a healthier, more productive animal.

Protecting Food Security & The Agriculture Economy

Without proper vaccines, U.S. pigs are at a severe risk of death. These deaths result in direct impacts on the United States’ economy as well as food supply. By working to develop safe and effective vaccines for various swine diseases, Aptimmune’s work ensures the viability of this important food source.

Support from the Missouri Technology Corporation

Aptimmune’s work requires significant research and development. The Missouri Technology Corporation has played an important role in making this work possible by investing in Aptimmune’s Series B raise.

This funding allowed Aptimmune to establish a Master Cell Stock, the foundation for their vaccine portfolio, and to develop individual vaccines for launch into the marketplace. Without this funding, Aptimmune would not be in a position to develop a vaccine against African Swine Fever, a swine disease that is currently ravaging Asia and is likely to infect the U.S. swine herd. Without a vaccine, U.S. pigs are at severe risk of death, which will have a direct impact on US and food security.

Investing in Innovation

Supporting companies like Aptimmune and the centers that serve them is a critical component of an effective economic development strategy. Support and investment from the Missouri Technology Corporation plays a key role in our state’s ability to attract and retain innovators and job creators.

MTC's investment in Aptimmune’s Series B raise played a significant role in Aptimmune’s decision to relocate corporate headquarters from Champaign, IL to St. Louis, MO. Aptimmune leadership said the move was due in large part to the exceptional financial and logistics support the company has received from investors and other businesses in the St. Louis area.